TherapeuticsMD (TXMD) Receivables (2010 - 2025)

TherapeuticsMD's Receivables history runs 16 years deep, the most recent figure standing at $20.8 million for Q4 2025.

• Quarterly Receivables fell 10.25% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.8 million (down 10.25% YoY) and the FY2025 annual result came in at $20.8 million, down 10.25% from the prior year.
• Receivables was $20.8 million for Q4 2025 at TherapeuticsMD, down from $23.1 million in the prior quarter.
• Across five years, Receivables topped out at $45.8 million in Q2 2022 and bottomed at $20.8 million in Q4 2025.
• A 5-year average of $32.3 million and a median of $33.6 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2021 — Receivables surged 83.05% — and 2022, when it dropped 14.02%.
• TherapeuticsMD's Receivables stood at $36.2 million in 2021, then retreated by 11.11% to $32.2 million in 2022, then slipped by 23.3% to $24.7 million in 2023, then slipped by 6.2% to $23.1 million in 2024, then slipped by 10.25% to $20.8 million in 2025.
• Business Quant data shows TXMD's Receivables at $20.8 million in Q4 2025, $23.1 million in Q4 2024, and $24.7 million in Q4 2023.